Schrödinger Q1 ACV $28.4M (+12%), drug disc. rev surges to $22.9M, net loss $60M, FY guide maintained

Schrodinger, Inc.

2026-Q1 EPS reported -$0.81 revenue$58,587,000

ACV $28.4M (+12% YoY); software revenue $35.6M (-21%) reflecting hosted transition.
Drug discovery revenue surged to $22.9M from $10.2M on deferred revenue recognition and program discontinuation.
Net loss $60.0M vs $59.8M; cash and securities $406M.
Maintained FY2026 guidance: ACV $218-228M (10-15% growth), drug discovery revenue $55-65M.
Planned summer launch of Bunsen agentic AI co-scientist; Lilly's $2.3B Ajax acquisition validates platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Schrodinger, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 5, 2026, Schrödinger, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Schrodinger, Inc. filing history →

Source: SEC EDGAR

accession 0001490978-26-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.